#USA #Baltimore #SereNeuro Therapeutics #SN101 #SN102

SereNeuro Therapeutics Shifts the Focus on Pain Management

In a recent announcement, SereNeuro Therapeutics, a biotechnology company focused on developing innovative non-opioid therapies for pain, has successfully completed its oversubscribed pre-seed financing round. This funding will significantly advance its lead program, SN101, towards Investigational New Drug (IND)-enabling studies while also bolstering its second program, SN102.

Exploring the Pain-Management Frontier

SereNeuro is pioneering a first-in-class, non-opioid therapy specifically designed to target chronic joint pain. The cornerstone of this initiative is SN101, which utilizes living human sensory neurons derived from induced pluripotent stem cells (iPSCs). What sets SN101 apart from conventional analgesics is that it not only targets pain signaling but also aims to preserve joint structure, providing a dual benefit to patients suffering from chronic joint pain.

Daniel Saragnese, CEO and co-founder of SereNeuro, mentioned, "Non-opioid pain therapeutics have gained substantial traction within the biotech landscape this year." He highlighted successful IPOs and multi-million dollar financings within this niche, underscoring the industry's shift towards non-addictive pain management solutions. In contrast to many existing therapies, SN101 is engineered to provide pain relief without the destructive side effects typically associated with opioid treatments.

The Science Behind SN101

SN101's unique formulation consists of human pain-sensing neurons that replicate the complete pain-channel identity of native human dorsal root ganglion neurons. These sensory neurons include critical sodium channel variants, Nav1.7, Nav1.8, and Nav1.9, which are essential for modulating pain responses. What began as an exploration into neuron functions transitioned into a promising therapy when researchers observed its therapeutic effects in joint pain models while testing the cells.

Additionally, work on SN102 is underway, aimed at treating trigeminal neuralgia and other forms of neuropathic pain. Dr. Zhuolun (Poppy) Wang, another co-founder of SereNeuro, articulated the vision for SN102, stating, "Our objective is to develop a single treatment that effectively reduces pain signaling in trigeminal neuralgia, without impairing normal sensory function."

The development of SN102 has received support from the National Institutes of Health (NIH) through their Small Business Innovation Research (SBIR) program. This comes under the NIH HEAL Initiative, aiming to generate impactful non-addictive treatment methods, addressing the opioid crisis through scientific solutions.

The Future Path for SereNeuro

In addition to the promising developments within its product pipeline, SereNeuro gained recognition by being selected for an Innovation Spotlight at the 2026 Cell and Gene Meeting on the Mesa. This opportunity places the spotlight on their innovative research and advancements within the field.

The pre-seed funding round involved participation from several Maryland-based venture firms and physician investors who structured investments under Maryland's Biotechnology Investment Incentive Tax Credit, which encourages growing biotech firms like SereNeuro in Opportunity Zones.

As the company moves forward, it will not only push the boundaries of non-opioid therapies but also bring hope for millions suffering from chronic pain conditions. With the backing of innovative funding and a dedicated team, SereNeuro Therapeutics is positioned to make a notable impact in the realm of pain management.

For further information about their groundbreaking work, visit their official website at www.sereneuro.com.